Why the study?
Can Cardiac [123I] MIBG scintigraphy detect and monitor cardiac sympathetic hyperactivity in a patient with Guillain-Barré syndrome?
Can Cardiac [123I] MIBG scintigraphy detect and monitor cardiac sympathetic hyperactivity in a patient with Guillain-Barré syndrome?
Cardiac [123I] MIBG scintigraphy can be a useful imaging modality to assess and monitor cardiac sympathetic hyperactivity in patients with Guillain-Barré syndrome.
Answers are grounded in this paper and cite their sources.
May support MIBG scintigraphy for monitoring sympathetic hyperactivity in GBS; hypothesis-generating and requires prospective validation.
A 31-year-old woman gradually developed weakness in the lower extremities and gait disturbance. Subsequently, the patient developed severe constipation and hypertension with tachycardia. Nerve conduction studies revealed demyelinating polyneuropathy. Serum anti-GQ1b IgG antibody was detected. The levels of plasma noradrenaline and dopamine and urinary noradrenaline were elevated. Cardiac [(123)I] metaiodobenzylguanidine (MIBG) scintigraphy showed a normal H/M rate at the early phase and an elevated washout rate. According to these findings, the patient was diagnosed with Guillain-Barré syndrome with cardiac sympathetic hyperactivity. During convalescence, the plasma and urine catecholamine levels fell within the reference ranges, and MIBG scintigraphy showed a decreased washout rate.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: